Its only a phase 1/2 trial, but private company Magellan had some positive results in its off the shelf allogeneic adipose-derived mesenchymal stem cell treatment of knee osteoarthritis. This is a massive potential application and market I would love Mesoblast to explore in the future:
https://www.oarsiopenjournal.com/article/S2665-9131(24)00067-0/fulltext#%20
75% of participants who’d received MSC cells exhibited improvement in pain and function by the usual patient clinical scaling measures - with sustained pain improvement of 58% at 12 months. MRI scans of the participants’ knees also indicated improvements in cartilage volume and quality.
A small trial but worth mentioning.
Cell Therapy News/Articles, page-17850
-
- There are more pages in this discussion • 180 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |